TICKERNERD
Menu
VERAVERAHealthcare · Biotechnology

VERA Stock Forecast: Vera Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$32
+3.25% on the day

The 14 Wall Street analysts covering Vera Therapeutics, Inc. hold a median 12-month price target of $79 — +144.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.3B
Ticker Nerd rank
26 / 100
Median analyst target
$79
Analysts covering
14
Total return, dividends reinvested
1W
+2.0%
1M
−13.2%
YTD
−36.3%
1Y
+42.7%
From 52W high
−42.0%
From 52W low
+51.2%
$21
$56
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VERA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vera Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
63
Accruals
55
Volatility
49
Value
46
Issuance
45
Size
35
Revisions
34
Quality
32
Growth
22

Momentum (63): The shares have been drifting up relative to others.

Growth (22): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VERA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VERA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100Oct 25Jan 26Apr 26Jul 26VERAHigh $100Median $79Low $34

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says14 analysts
13 Buy1 Hold0 Sell
Low $34Median $79High $100

The green dot is the last close — the median target sits +144.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
17 Aug 2026WedbushReiteratesNeutral$34
12 Aug 2026HC Wainwright & Co.MaintainsBuy$125 → $90
11 Aug 2026WedbushMaintainsNeutral$43 → $34
8 July 2026GuggenheimMaintainsBuy$56 → $76
8 July 2026GuggenheimMaintainsBuy—
8 July 2026HC Wainwright & Co.MaintainsBuy$110 → $125
8 July 2026HC Wainwright & Co.MaintainsBuy—
8 July 2026TD CowenMaintainsBuy$73 → $78
8 July 2026TD CowenMaintainsBuy—
8 July 2026WedbushMaintainsNeutral—
8 July 2026WedbushMaintainsNeutral$35 → $43
7 July 2026B of A SecuritiesMaintainsBuy—
7 July 2026B of A SecuritiesMaintainsBuy$65 → $70
15 May 2026Evercore ISI GroupMaintainsOutperform—
11 Mar 2026Wolfe ResearchUpgradeOutperform—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—
19 Dec 2025B of A SecuritiesMaintainsBuy—
19 Dec 2025Goldman SachsMaintainsBuy—
19 Dec 2025JP MorganMaintainsOverweight—
11 Dec 2025WedbushMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VERA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

VERA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

Vera Therapeutics, Inc. (VERA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.9×

Cheaper than 91% of US stocks

Price / sales
—
Price / book
5.7×

Cheaper than 19% of US stocks

EV / EBITDA
−4.6×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−91.8%

Higher than 14% of US stocks

Return on assets
−46.8%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

VERA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VERAVera Therapeutics, Inc.$2.3B
26
MLYSMineralys Therapeutics, Inc.$2.3B
21
URGNUroGen Pharma Ltd.$2.3B
82
COAGHemab Therapeutics Holdings, Inc.$2.3B
2
RAPPRapport Therapeutics, Inc.$2.2B
43
KODKodiak Sciences, Inc.$2.3B
47
AUPHAurinia Pharmaceuticals, Inc.$2.2B
96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vera Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VERA news & analysis

Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy

Seeking Alpha · 17 Aug 2026positive

Vera Therapeutics was upgraded to Buy following TRUTAKNA's FDA approval and encouraging exploratory eGFR data from the FDA showing stable kidney function. Full phase 3 data is expected in Q3 2026, and TRUTAKNA faces competition from Otsuka's VOYXACT and Vertex's povetacicept but holds a commercial head start and broad label.

Why it matters — The FDA's supportive eGFR analysis and TRUTAKNA's commercial head start strengthen the bull case for VERA ahead of the full phase 3 readout in Q3 2026.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 7 Aug 2026neutral

Vera Therapeutics announced that on August 3, 2026, its Compensation Committee granted inducement awards to Dr. Nancy Bowman, consisting of non-qualified stock options for 63,011 shares of Class A common stock and RSUs for 44,987 shares, under Nasdaq Listing Rule 5635(c)(4).

Why it matters — The inducement grant signals the company's recruitment of a new executive, which VERA watchers would note as a corporate governance and leadership development.

FAQ

Frequently asked questions about VERA stock

What is the VERA stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Vera Therapeutics, Inc. have a median 12-month price target of $79, with estimates ranging from $34 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VERA stock a buy right now?

Of the 14 analysts covering Vera Therapeutics, Inc., 13 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vera Therapeutics, Inc. 26 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VERA?

As at 22 Aug 2026, Vera Therapeutics, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (63 of 100).

Will VERA stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +144.8% from the last close, and Ticker Nerd's factor model ranks Vera Therapeutics, Inc. 26 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VERA stock forecast for 2030?

No analyst covering Vera Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VERA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $100 over the next 12 months.

How has VERA stock performed over the past year?

Vera Therapeutics, Inc. returned +42.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vera Therapeutics, Inc. do?

Vera Therapeutics Inc. is a biotechnology company engaged in the research and development of transformative therapies aimed at treating immune-mediated diseases.

What is the latest news on VERA?

The most recent item we track (Seeking Alpha, 17 Aug 2026): "Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy". Vera Therapeutics was upgraded to Buy following TRUTAKNA's FDA approval and encouraging exploratory eGFR data from the FDA showing stable kidney function. Full phase 3 data is expected in Q3 2026, and TRUTAKNA faces competition from Otsuka's VOYXACT and Vertex's povetacicept but holds a commercial head start and broad label.

Company

About Vera Therapeutics, Inc.

Vera Therapeutics Inc. is a biotechnology company engaged in the research and development of transformative therapies aimed at treating immune-mediated diseases. The primary focus of Vera Therapeutics is to address unmet medical needs, particularly in the treatment of conditions such as immunoglobulin A nephropathy (IgAN), a kidney disorder that can lead to irreversible damage and renal failure. The company's lead asset, atacicept, is a novel, biologic therapeutic that targets specific pathways implicated in the pathogenesis of autoimmune diseases. Vera Therapeutics operates at the forefront of the biotechnology sector, a field characterized by rapid innovation and significant impact on healthcare and disease management. By advancing clinical trials and pursuing regulatory approval for their therapies, Vera Therapeutics contributes significantly to the potential revolutionizing of treatment options for patients with chronic conditions. Founded with a commitment to improving patients' lives, Vera Therapeutics plays a crucial role in expanding the biotech landscape, aiming to bring new hope and effective solutions to markets historically underserved by traditional pharmaceutical approaches.

CEO Dr. Marshall W. Fordyce M.D. · 361 employees · United States · https://veratx.com